Cosmetic Injections Guide: Botox and Fat Transfer

Botulinum Toxin (Botox)

The administration of Botulinum Toxin (commonly known as Botox) is one of the most widely performed non-surgical procedures for reducing facial wrinkles. This toxin is a purified, sterile protein derived under controlled laboratory conditions from the bacterium Clostridium botulinum. When injected in minute quantities into targeted facial muscles, it blocks nerve signals responsible for muscle contraction for several months. By temporarily immobilizing these muscles, unwanted dynamic facial wrinkles are significantly softened.

There are 43 distinct muscles in the human face. Precise injection placement is critical so that only wrinkle-inducing muscles are selectively weakened, preserving natural facial expressions.

Common Clinical Applications of Botulinum Toxin:

• Glabellar lines (frown lines between the eyebrows)

• Periorbital lines (crow’s feet around the eyes)

• Horizontal forehead lines

• Platysmal neck bands

Onset and Duration:

Initial results become noticeable 3 to 7 days post-injection, with full therapeutic effects settling within 7 to 10 days. The duration of action typically spans 3 to 6 months, after which muscle mobility and associated wrinkles gradually return. The longevity of results varies based on skin thickness, skin type, and pre-existing wrinkle depth.

Contraindications for Botox Injections:

• Patients under 18 or over 65 years of age

• Individuals with known allergies to cow’s milk protein

• Patients who have previously experienced severe hypersensitivity to any botulinum neurotoxin product

• Active skin infections at the proposed injection sites

• Pregnant or lactating women

FDA Approval History & Medical Background

Botulinum toxin—much like digitalis or atropine—is a natural compound initially recognized for its toxic properties before being refined for medical use. The toxin was first identified during food poisoning outbreaks in the early 19th century.

• 1822: The neurotoxic effects of botulinum toxin following sausage consumption were first described, giving rise to the name botulism.

• 1895: Clostridium botulinum was identified as the causative bacterium.

• 1940s: Botulinum Toxin Type A was isolated and purified.

• 1960s–1970s: Animal studies led to clinical testing for strabismus (crossed eyes).

• 1989: Approved by the U.S. FDA under the trade name Oculinum for treating strabismus and blepharospasm. The formulation was later acquired by Allergan and rebranded as BOTOX®, becoming the gold standard for focal dystonias and pediatric muscle spasticity.

• 2002: The FDA approved Botox Cosmetic for temporary improvement of moderate to severe glabellar frown lines in adults aged 18 to 65.

• 2004: The FDA approved Botox for primary axillary hyperhidrosis (excessive underarm sweating).

Globally Recognized Approved Neurotoxins:

• BOTOX® (Allergan, USA) – Approved 1989

• Dysport® (Ipsen, UK) – Approved 1991

• Myobloc® / Neurobloc® (Solstice/Elan, USA) – Approved 2000

• Xeomin® (Merz, Germany) – Approved 2005

Safety Warning: Unlicensed or uncertified formulations (such as unauthorized generic imports) lack standardized dosing units and pose significant health risks. Their clinical use is strongly advised against.

Updated Generic Nomenclature (FDA 2009):

• Botox $\rightarrow$ OnabotulinumtoxinA

• Dysport $\rightarrow$ AbobotulinumtoxinA

• Myobloc / Neurobloc $\rightarrow$ RimabotulinumtoxinB

Clinical Insights & Advanced Botox Applications

• Long-Term Efficacy: Repeated maintenance treatments over several years show sustained patient response without loss of safety, reduction in quality of life, or requirement for escalating doses. Long-term studies indicate increased duration of effect and enhanced functional improvement over time.

• Male Dosage: Male facial muscles are typically denser; therefore, men often require higher units to achieve comparable results.

• Crow’s Feet: Longevity in the periorbital area is slightly shorter than in the forehead, typically lasting 3 to 4 months.

• Pre-Treatment Rule: Discontinue aspirin, NSAIDs, and anticoagulants at least 2 weeks prior to treatment to minimize bruising.

• Bunny Lines: Vertical lines formed on the upper nose during squinting (“bunny lines”) should be treated concurrently with glabellar frown lines.

• Nostril Flaring: In individuals whose nostrils involuntarily flare during speech or smiling—often projecting unintended sternness or stress—botox injections into the dilator naris muscle can soften this movement.

• Nasal Tip Elevation: Aging, gravity, and hyperactive depressor septi nasi muscles can cause the nasal tip to droop, sometimes exaggerated during talking or smiling (occasionally accompanied by a gummy smile or horizontal upper lip crease). Injecting Botox into the depressor septi nasi relaxes the downward pull, elevating the nasal tip. (Note: If the tip does not move dynamically during facial expressions, Botox will not elevate the tip).

• Marionette Lines: Downward turning mouth corners and marionette lines extend from lip corners to the jawline, creating a sad or harsh expression. While primary structural correction requires facelifts, resurfacing, or dermal fillers, adjunctive Botox relaxes surrounding depressor muscles, extending the longevity of these treatments.

Fat Transfer & Dermal Fat Grafting

Autologous fat is one of the safest, most natural materials for restoring lost facial volume, filling deep structural grooves, and enhancing body contours. It is utilized in two primary forms: Dermal Fat Grafting and Autologous Fat Injection (Micro-fat Transfer).

Target Treatment Areas:

• Face: Glabellar grooves, nasolabial folds (smile lines), cheeks, tear troughs (under-eye hollows), lips, and structural volume deficits.

• Dorsum of Hands: Hand rejuvenation to cover prominent veins and tendons.

• Body Contouring: Selected structural body volume enhancements.

Harvesting & Preparation Methods

A) Dermal Fat Graft:

A small skin segment (typically from the lower abdomen) is harvested along with underlying dermal and subdermal fat tissue. The donor site is sutured closed, and the harvested tissue is sculpted to match the target defect.

B) Autologous Free Fat Injections (Micro-fat):

Under local anesthesia, fat is harvested from donor sites (abdomen, thighs, or flanks) using ultra-fine micro-cannulas ($2\text{ mm}$) attached to low-pressure syringes. The aspirated fat is processed to remove fluids and oil, yielding a concentrated, purified micro-fat gel. This procedure requires no surgical skin incisions or external sutures.

Application Techniques & Surgical Methods

• Dermal Fat Grafting: A precise incision is made over the receiving area. The recipient bed is dissected, and the prepared dermal-fat block is positioned and secured.

• Fat Injection: Purified fat is injected into target tissue planes using fine blunt cannulas. The technique requires zero surgical incisions or sutures.

Retention and Longevity

• Dermal Fat Graft: A portion is reabsorbed during early healing, while the remaining integrated graft provides permanent structural volume.

• Fat Injection: Approximately 40% to 50% of injected fat volume is naturally reabsorbed over 1 to 3 months. The remaining 50% to 60% establishes a permanent blood supply and stays indefinitely. Repeat touch-up sessions may be scheduled if additional volume is desired.

Potential Complications:

• Dermal Fat Grafting: Rarely, a localized firm nodule or palpable band may form. Graft rejection is extremely rare.

• Fat Injections: Minor surface irregularities or subtle contour banding may occur in rare instances. Infection rates are exceptionally low under sterile protocols.

Post-Procedure Guidelines (Fat Transfer & Injections)

1. Cold Compresses: Apply cold compresses to the treated area for 5 to 10 minutes every half hour during waking hours for the first 48 hours.

2. Swelling Progression: Swelling peaks over the first 72 hours and gradually subsides over 10 to 15 days.

3. Bruising: Mild bruising is self-limiting and resolves naturally without intervention.

4. Avoid Warm Compresses: Heat application is strictly prohibited, as it destroys transferred fat cells.

5. Heat & Sun Exposure: Avoid saunas, hot tubs, steam rooms, and direct sun exposure for 4 to 6 weeks.

6. Donor Site Care: Serosanguinous fluid drainage from donor sites during the first few hours is normal; simply replace saturated sterile dressings.

7. Cosmetics: Avoid applying cosmetics or makeup over treated facial areas for 10 to 12 days.